Splenopentin diacetate is a synthetic immunomodulatory pentapeptide corresponding to residues 32-36 of the spleen hormone spleen protein. It affects early T and B cell differentiation, thereby increasing the number of antibody-forming cells in gamma-irradiated mice.
in vitro
Splenopentin (1-100 μM) augments human NK cells and has no cytotoxicity. Splenopentin (0.1 ng/mL-10 μg/mL; 3 h) induces phenotypic differentiation of both T- and B -cell precursor cells.
in vivo
Splenopentin (1 mg/kg; ip three times a week for 7-90 d) accelerates Langerhans cell recruitment and leads to pretreatment levels of Langerhans cell (LC) density in the skin of mice. Splenopentin (0.01-100 μg per mouse; ip) has no demonstrable effect on neuromuscular transmission of mice.
Animal Model:
Female Balb /c/Bln mice were injected Cyclophosphamide or Dexamethasone for 5 consecutive days
Dosage:
1 mg /kg
Administration:
Ip three times a week for 7-90 days
Result:
Reached the normal number of epidermal LCs at 28 days after the beginning of Cyclophosphamide treatment. Accelerated restoration process and reached the normal LC density in the skin after 70 days in Dexamethasone treatment grops.
